Aethlon Medical, Inc. (AEMD)

In our clinic reviewing the AEMD-2022-06 protocol, the independent DSMB recommendation to advance from cohort 2 to cohort 3 without any device-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) is a solid technical checkpoint. Three Hemopurifier treatments over one week across active Australian sites provides a clear procedural baseline. However, preparing for potential investigational use against the Bundibugyo Ebola outbreak requires strict regulatory alignment with global health authorities before any real-world emergency deployment can materialize.

On our desk, AEMD's market valuation is a classic micro-cap trap. While the stock sits around $2.89 with a depressed market cap, the trailing net losses of roughly $6.94M and a Q1 EPS miss of ($4.02) underscore deep financial strain. The YTD return shows a severe ~79% collapse from January levels, and upcoming votes on share authorization increases point directly to heavy dilution risks that long-term investors are heavily penalizing.

Watching the 50-day MA and recent historical prices, the trading volume spikes around corporate updates—such as the March fiscal year-end results and the August Q1 earnings call—highlight intense retail speculation. Between the ongoing evaluation of strategic opportunities by Maxim Group and the looming need to approve inducement warrants and share pools for employee retention, the risk profile heavily tilts toward extreme volatility and capital structure dilution.